BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.

Saved in:
Bibliographic Details
Title: BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.
Authors: Verstovsek S; The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Al-Ali HK; Krukenberg Cancer Center, University Hospital, Halle, 33790, Germany., Mascarenhas J; Icahn School of Medicine at Mount Sinai, NY 10029, USA., Perkins A; Australian Centre for Blood Diseases, Monash University, Victoria, 3294, Australia., Vannucchi AM; University of Florence, Florence, 50121, Italy., Mohan SR; Vanderbilt University Medical Center, Nashville, TN 37232, USA., Scott BL; Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA., Woszczyk D; Hematology Department, University of Opole, Opole, 45-040, Poland., Koschmieder S; Department of Hematology, Oncology, Haemostaseology & Stem Cell Transplantation (Department of Medicine IV), Faculty of Medicine, RWTH University Aachen, Aachen, 52062, Germany., García-Delgado R; Virgen de la Victoria University Hospital, Málaga, 29010, Spain., László R; Josa András Teaching Hospital, Nyíregyháza, 4400, Hungary., McGreivy JS; Kartos Therapeutics, Inc., Redwood City, CA 94065, USA., Rothbaum WP; Kartos Therapeutics, Inc., Redwood City, CA 94065, USA., Kiladjian JJ; Saint-Louis Hospital & Université Paris Cité, Paris, 75010, France.
Source: Future oncology (London, England) [Future Oncol] 2022 Nov 23. Date of Electronic Publication: 2022 Nov 23.
Publication Type: Journal Article; Review
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1744-8301
DOI:10.2217/fon-2022-0901